Page 31 - 2019_02-Haematologica-web

CD30+ primary cutaneous LPD
Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood. 2009;113(4):856-865.
88. Tohda S, Nara N. Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. Leuk Lymphoma. 2001;42(3):467-472.
89. Kamstrup MR, Biskup E, Gniadecki R. Notch signalling in primary cutaneous CD30+ lymphoproliferative disorders: a new therapeutic approach? Br J Dermatol. 2010;163(4):781-788.
90. Sharpless NE, DePinho RA. The INK4A/ARF locus and its two gene prod- ucts. Curr Opin Genet Dev. 1999;9(1):22-30.
91. Scarisbrick JJ, Woolford AJ, Calonje E, et al. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syn- drome. J Invest Dermatol. 2002;118(3):493- 499.
92. Navas IC, Algara P, Mateo M, Martinez P, Garcia C, Rodriguez JL, et al. p16(INK4a) is selectively silenced in the tumoral progres- sion of mycosis fungoides. Lab Invest. 2002;82(2):123-132.
93. Navas IC, Ortiz-Romero PL, Villuendas R, et al. p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides. Am J Pathol. 2000;156(5):1565-1572.
94. Gallardo F, Esteller M, Pujol RM, et al. Methylation status of the p15, p16 and MGMT promoter genes in primary cuta- neous T-cell lymphomas. Haematologica. 2004;89(11):1401-1403.
95. Laharanne E, Chevret E, Idrissi Y, et al. CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lym- phoma. Mod Pathol. 2010;23(4):547-558.
96. Nicolae-Cristea AR, Benner MF, Zoutman WH, et al. Diagnostic and prognostic signif-
icance of CDKN2A/CDKN2B deletions in patients with transformed mycosis fun- goides and primary cutaneous CD30-posi- tive lymphoproliferative disease. Br J Dermatol. 2015;172(3):784-788.
97. Szuhai K, van Doorn R, Tensen CP, et al. Array-CGH analysis of cutaneous anaplastic large cell lymphoma. Methods Mol Biol. 2013;973:197-212.
98. Mao X, Orchard G, Lillington DM, et al. Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma. Genes Chromosomes Cancer. 2003;37(2): 176-185.
99. Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus rec- ommendations for the treatment of pri- mary cutaneous CD30-positive lympho- proliferative disorders: lymphomatoid papulosis and primary cutaneous anaplas- tic large-cell lymphoma. Blood. 2011;118 (15):4024-4035.
100.Vu K, Ai W. Update on the treatment of anaplastic large cell lymphoma. Curr Hematol Malig Rep. 2018;13(2):135-141.
101.Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lym- phoma (ALCANZA): an international, open- label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555-566.
102. Enos TH, Feigenbaum LS, Wickless HW. Brentuximab vedotin in CD30(+) primary cutaneous T-cell lymphomas: a review and analysis of existing data. Int J Dermatol. 2017;56(12):1400-1405.
103. Nairismagi M, Gerritsen ME, Li ZM, et al. Oncogenic activation of JAK3-STAT signal- ing confers clinical sensitivity to PRN371, a
novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. Leukemia. 2018;32(5):1147-1156.
104. Mosse YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14(6):472-480.
105.Moretta A, Parolini S, Castriconi R, et al. Function and specificity of human natural killer cell receptors. Eur J Immunogenet. 1997;24(6):455-468.
106. Poszepczynska-Guigne E, Schiavon V, D'Incan M, et al. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. J Invest Dermatol. 2004;122(3): 820-823.
107.Ott CJ, Wu CJ. HDAC inhibitors finally open up: chromatin accessibility signatures of CTCL. Cancer Cell. 2017;32(1):1-3.
108. Schcolnik-Cabrera A, Dominguez-Gomez G, Duenas-Gonzalez A. Comparison of DNA demethylating and histone deacety- lase inhibitors hydralazine-valproate versus vorinostat-decitabine incutaneous t-cell lymphoma in HUT78 cells. Am J Blood Res. 2018;8(2):5-16.
109. Kim SR, Lewis JM, Cyrenne BM, et al. BET inhibition in advanced cutaneous T cell lym- phoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition. Oncotarget. 2018;9(49):29193-29207.
110.Moyal L, Yehezkel S, Gorovitz B, et al. Oncogenic role of microRNA-155 in myco- sis fungoides: an in vitro and xenograft mouse model study. Br J Dermatol. 2017; 177(3):791-800.
haematologica | 2019; 104(2)
235